Bevacizumab exerts anti-angiogenic effects in cancer patients by inhibiting vascular endothelial growth factor (VEGF). However, its use is still limited due to the development of resistance to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback